Citius Oncology expands LYMPHIR availability through Named Patient Programs in Europe, Middle East.

Citius Oncology, a specialty biopharmaceutical company, has established an exclusive relationship with Integris Pharma to make LYMPHIR available to eligible patients in Greece, Cyprus, and other Balkan countries through Named Patient Programs. The partnership covers 11 countries and marks the company's footprint in the region. Citius Oncology is focused on developing and commercializing targeted oncology therapies.

Citius Oncology, Inc. (Nasdaq: CTOR), a specialty biopharmaceutical company focused on developing and commercializing targeted oncology therapies, has established an exclusive relationship with Integris Pharma to make LYMPHIR available to eligible patients in Greece, Cyprus, and other Balkan countries through Named Patient Programs (NPPs). This strategic partnership covers 11 countries, marking the company's significant footprint in the region.

The agreement with Integris Pharma, a privately-owned specialty pharmaceutical company, enables Citius Oncology to expand access to LYMPHIR in Southern Europe. Named Patient Programs are recognized pathways that provide early access to promising new medicines before full marketing authorization and commercial availability. These programs are particularly beneficial for patients with serious illnesses who need immediate treatment options Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe^[1].

LYMPHIR, a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), was approved by the FDA in August 2024 for use in Stage I-III disease after at least one prior systemic therapy. The drug is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments, specifically targeting tumor cells and immunosuppressive regulatory T-cells .

The partnership with Integris Pharma will facilitate the distribution of LYMPHIR through NPPs in Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro, and North Macedonia. Integris Pharma's expertise in oncology, hematology, and rare diseases, along with its robust presence in these markets, makes it an ideal distribution partner for Citius Oncology. The company's end-to-end support, including regulatory and market access management, pricing and reimbursement navigation, and pharmacovigilance, ensures that innovative therapies like LYMPHIR reach patients quickly and effectively Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe^[1].

Citius Oncology's focus on expanding access to LYMPHIR through NPPs outside the United States underscores its commitment to patient access and strategic market positioning. The company is actively engaging with regional distribution partners in Europe, South America, and the Middle East to accelerate awareness, strengthen clinical adoption, and build relationships with leading treatment centers Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe^[1].

About Citius Oncology, Inc.
Citius Oncology is a biopharmaceutical company specializing in the development and commercialization of novel targeted oncology therapies. Its primary asset, LYMPHIR, was approved by the FDA in August 2024 for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. The initial market for LYMPHIR is estimated to exceed $400 million, with significant growth potential .